telmisartan has been researched along with Atherogenesis in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH | 1 |
| Guo, J; Jia, Y; Li, S; Zhu, Z | 1 |
| Fang, D; He, Z; Huang, L; Jiang, C; Jin, Q; Jin, Z; Liu, Y; Song, X; Wang, F; Wu, J; Yang, Y | 1 |
| Achenbach, S; Cicha, I; Garlichs, CD; Klinghammer, L; Lewczuk, P; Raaz-Schrauder, D; Urschel, K | 1 |
| Kaul, U; Mansoor, A; Sabbah, ZA | 1 |
| Dika, Z; Fodor, L; Ivković, V; Jelaković, B; Laganović, M; Perkov, D; Premužić, V; Vrkić, TZ; Zivko, M | 1 |
| Brunner, HR; Foster, C; Huo, Y; Michel, MC | 1 |
| Brar, MS; Chan, YK; Chen, Y; El-Nezami, H; Kirjavainen, PV; Leung, FC; Li, D; Peng, J | 1 |
| Cohn, JN | 1 |
| Fischer, JW; Melchior-Becker, A; Nagy, N | 1 |
| Arnheim, K | 1 |
| Ho, C; Kurtz, TW; Ohishi, M; Rakugi, H; Yamamoto, K | 1 |
| Anderson, C; Cowan, BR; Doughty, RN; Jennings, GL; Krittayaphong, R; Lonn, E; Marwick, TH; Reid, CM; Sanderson, JE; Schmieder, RE; Teo, K; Wadham, AK; Worthley, SG; Young, AA; Yu, CM; Yusuf, S | 1 |
| Ceska, R; Krutská, S; Vrablík, M; Zlatohlávek, L | 1 |
| Enomoto, S; Fukuda, D; Hirata, Y; Nagai, R; Sata, M | 1 |
| Baumhäkel, M; Böhm, M; Kratz, M; Schlimmer, N | 1 |
| Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kawasaki, S; Kinoshita, H; Matsumura, T; Motoshima, H; Nishikawa, T; Nishimaki-Mogami, T; Senokuchi, T; Taketa, K | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Mizuguchi, T; Namiki, T; Narumi, H; Ohtsuka, M; Takano, H | 1 |
| Ieiri, I; Iwase, M; Kitazono, T; Matsuyama, N; Ohdo, S; Sonoki, K; Takata, Y | 1 |
| Aksoy, A; Becher, UM; Lütjohann, D; Mueller, CF; Nickenig, G; Tiyerili, V; Wassmann, S | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Hirata, K; Inoue, N; Kawashima, S; Sasaki, N; Shinohara, M; Takaya, T; Toh, R; Yamashita, T; Yokoyama, M | 1 |
| Kurtz, TW | 1 |
| Bea, F; Blessing, E; Gräfe, J; Isermann, B; Katus, HA; Kinscherf, R; Kranzhöfer, R; Kreuzer, J; Marx, N; Preusch, M; Rosenfeld, ME; Weber, CM | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Iwanami, J; Kanno, H; Mogi, M; Tomono, Y | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, H; Yoshida, K | 1 |
3 review(s) available for telmisartan and Atherogenesis
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Culture Techniques; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Gene Knockout Techniques; Glucose; Humans; Hypertension; Kidney; Lipid Metabolism; Metabolic Diseases; Oxadiazoles; Renin-Angiotensin System; Stroke; Telmisartan | 2016 |
[Comprehensive management of cardiovascular risk. Focusing on telmisartan].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Risk Factors; Telmisartan | 2010 |
New treatment strategies for patients with hypertension and insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; PPAR gamma; Renin-Angiotensin System; Telmisartan | 2006 |
4 trial(s) available for telmisartan and Atherogenesis
| Article | Year |
|---|---|
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial.
Topics: Amlodipine; Atherosclerosis; Cardiovascular Diseases; Fasting; Glucose; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insulin Resistance; Prediabetic State; Rosuvastatin Calcium; Telmisartan | 2022 |
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Diabetes Complications; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Ramipril; Survival Analysis; Telmisartan; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Carotid Intima-Media Thickness; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Japan; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Telmisartan; Treatment Outcome | 2011 |
Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity.
Topics: Acetylcysteine; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Atherosclerosis; Benzimidazoles; Benzoates; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Group V Phospholipases A2; Human Umbilical Vein Endothelial Cells; Humans; Hypertension; Lipoproteins, LDL; Lysophosphatidylcholines; Male; Middle Aged; RNA, Messenger; Telmisartan; Tumor Necrosis Factor-alpha | 2012 |
19 other study(ies) available for telmisartan and Atherogenesis
| Article | Year |
|---|---|
Homocysteine promotes migration of adventitial fibroblasts via angiotensin II type 1 receptor activation to aggravate atherosclerosis.
Topics: Adventitia; Atherosclerosis; Fibroblasts; Homocysteine; Humans; Hyperhomocysteinemia; Receptor, Angiotensin, Type 1; Telmisartan | 2022 |
Folate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Folic Acid; Liposomes; Macrophages; Mice; Mice, Inbred C57BL; Telmisartan | 2019 |
Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis--influence on IP-10, TNF-α and MCP-1.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Chemokine CCL2; Chemokine CXCL10; Coronary Artery Disease; Female; Humans; Hypertension; Inflammation; Interleukin-6; Male; Middle Aged; Telmisartan; Tumor Necrosis Factor-alpha | 2013 |
Angiotensin receptor blockers - advantages of the new sartans.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Telmisartan; Tetrazoles; Treatment Outcome | 2013 |
Arterial stiffness in atherosclerotic renovascular hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aorta; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Determination; Essential Hypertension; Female; Humans; Hypertension; Hypertension, Renovascular; Longitudinal Studies; Male; Middle Aged; Pulse Wave Analysis; Renin-Angiotensin System; Risk Factors; Stents; Telmisartan; Vascular Stiffness | 2014 |
High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamno
Topics: Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Cholesterol; Colon; Diet, High-Fat; Fatty Acid-Binding Proteins; Female; Gastrointestinal Microbiome; Humans; Lacticaseibacillus rhamnosus; Mice; Mice, Inbred C57BL; Mice, Knockout; Pilot Projects; Probiotics; Telmisartan | 2016 |
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan; Treatment Outcome | 2008 |
Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Biglycan; Blood Pressure; Collagen; Extracellular Matrix Proteins; Lipid Metabolism; Male; Mice; Mice, Knockout; Proteoglycans; Telmisartan | 2010 |
[Erectile dysfunction as a harbinger of cardiovascular events. Long-term vascular protection with telmisartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Impotence, Vasculogenic; Male; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan | 2009 |
Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Atherosclerosis; Benzimidazoles; Benzoates; Cell Differentiation; Cell Division; CHO Cells; Cricetinae; Cricetulus; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NIH 3T3 Cells; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; Signal Transduction; Telmisartan; Umbilical Veins | 2009 |
The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Collagen; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan | 2010 |
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cholesterol; Drug Therapy, Combination; Endothelium, Vascular; Erectile Dysfunction; Free Radicals; Lipid Peroxides; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Ramipril; Renin-Angiotensin System; Telmisartan | 2011 |
Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Gene Expression Regulation; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; PPAR gamma; Telmisartan; Tumor Necrosis Factor-alpha | 2011 |
AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Experimental; Endothelium, Vascular; Female; Mice; Mice, Knockout; Oxidative Stress; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan | 2013 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Female; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Superoxides; Telmisartan | 2006 |
Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Early Growth Response Protein 1; Inflammation; Macrophages; Male; Mice; Mice, Transgenic; NF-kappa B; Nitric Oxide Synthase Type II; PPAR gamma; Renin-Angiotensin System; Telmisartan | 2008 |
Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Benzoates; Brain Ischemia; Cerebrovascular Circulation; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Mice; Mice, Knockout; Superoxides; Telmisartan | 2008 |
Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Benzimidazoles; Benzoates; Biphenyl Compounds; Disease Models, Animal; Hyperlipidemias; Male; Nitric Oxide; PPAR gamma; Rabbits; Telmisartan; Tetrazoles; Up-Regulation | 2008 |